Online ISSN: 2515-8260

Keywords : Metformin


STUDY ON EVALUATION OF MET FOR MINVERSUSINSUL IN THERAPYINTHE MANAGEMENT OF GESTATIONAL DIABETES

Dr. Divya Saraswat,Dr.Kavita Chhabra

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 1654-1658

BACKGROUND: Gestational Diabetes mellitus (GDM) is defined as Glucose
Intolerance, the valuesof plasma glucose falling in the range of Diabetes which is
observed and detected for the first
timeduringsecondorthirdtrimesterofpregnancy.GDMisquite
oftenassociatedwithhighermaternalandneonatalmorbiditiesin theshort andlong-term
andpredisposesbothwomen andchildto laterdevelopment of type 2 Diabetes
OBJECTIVE OF THE STUDY: the objective of our study is
tocomparematernalandneonataloutcomesinGDMpatientswhoareonmetforminandinsulin.
MATERIALS &METHODS: the study on evaluation of metformin versus insulin
therapy in themanagement of gestational diabetes was conducted in dept. of OBG Adesh
Institute of
MedicalSciences,Ambalaafterobtaininginstitutionalethicalcommitteeclearanceforaperiod
ofoneyearfromJanuary 2021 to December 2021 in the age group of 26-35 years.
Maternal and neonatal outcomesrecorded include: maternal: incidence of pre-eclampsia,
PIH, neonatal outcomes include: macrosomia,birth weight, the incidence of small for
gestational age, prematurity, Apgar score at the age of 5 min,hypoglycaemia. We also
compared the mode of delivery (spontaneous, assisted or caesarean section)between the
two groups. RESULTS & CONCLUSIONS: It is quite evident from in our study
thattherewerenostatisticallysignificantdifferencesinboththegroupswithrespecttomaternalc
omplications, mode of delivery and neonatal complications. In our study, we found that
the oral antidiabetic medication metformin is equally effective as insulin in the treatment
of GDM patients andwithout higher risks for maternal or neonatal complications.
However, further randomized clinicalstudies with large number of patients and with
long-term follow-up of children is needed to
determinetheroleofMetforminasanalternativetreatmenttoinsulinin GDMpatients

STUDY ON EVALUATION OF MET FOR MINVERSUSINSUL IN THERAPYINTHE MANAGEMENT OF GESTATIONAL DIABETES.

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 1654-1658

BACKGROUND: Gestational Diabetes mellitus (GDM) is defined as Glucose
Intolerance, the valuesof plasma glucose falling in the range of Diabetes which is
observed and detected for the first
timeduringsecondorthirdtrimesterofpregnancy.GDMisquite
oftenassociatedwithhighermaternalandneonatalmorbiditiesin theshort andlong-term
andpredisposesbothwomen andchildto laterdevelopment of type 2 Diabetes
OBJECTIVE OF THE STUDY: the objective of our study is
tocomparematernalandneonataloutcomesinGDMpatientswhoareonmetforminandinsulin.
MATERIALS &METHODS: the study on evaluation of metformin versus insulin
therapy in themanagement of gestational diabetes was conducted in dept. of OBG Adesh
Institute of
MedicalSciences,Ambalaafterobtaininginstitutionalethicalcommitteeclearanceforaperiod
ofoneyearfromJanuary 2021 to December 2021 in the age group of 26-35 years.
Maternal and neonatal outcomesrecorded include: maternal: incidence of pre-eclampsia,
PIH, neonatal outcomes include: macrosomia,birth weight, the incidence of small for
gestational age, prematurity, Apgar score at the age of 5 min,hypoglycaemia. We also
compared the mode of delivery (spontaneous, assisted or caesarean section)between the
two groups. RESULTS & CONCLUSIONS: It is quite evident from in our study
thattherewerenostatisticallysignificantdifferencesinboththegroupswithrespecttomaternalc
omplications, mode of delivery and neonatal complications. In our study, we found that
the oral antidiabetic medication metformin is equally effective as insulin in the treatment
of GDM patients andwithout higher risks for maternal or neonatal complications.
However, further randomized clinicalstudies with large number of patients and with
long-term follow-up of children is needed to
determinetheroleofMetforminasanalternativetreatmenttoinsulinin GDMpatients

EFFECT OF GLYCEMIC CONTROL ON VITAMIN B12 METABOLISM IN TYPE 2 DIABETES MELLITUS PATIENTS

Dhiraj Mahaseth, Vikas Kumar Gupta, Bijay Kumar Mahaseth, Ashish Kumar Sharma .

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 4981-4987

Background: Diabetes mellitus is a metabolic disorder due to absolute or relative insulin deficiency. Polyuria in type 2 DM leads to loss of important water soluble nutrients in urine. In view of widespread deficiency of vitamin B12 in our country and increasing prevalence of diabetes mellitus type 2, it is considered worthwhile to assess vitamin B12 status of patients with diabetes mellitus type 2.
Material and methods: Present study comprises of 60 subjects of both sexes whom 30 are healthy controls and 30 are clinically confirmed cases of diabetes mellitus, age group ranges from 40-70 yrs. Serum separated from plain vial after centrifugation was used for estimation of serum vitamin B12 by ELISA, Plasma glucose estimation by GOD-POD Method, End Point, Glycated hemoglobin by Boronate Affinity chromatography (NycoCard).
Result: In our study it was found that serum vitamin B12 (218.24 ± 68.31 pg/ml) was significantly lower in type2 diabetes mellitus patients compared to serum vitamin B12 (254.20 ± 64.89 pg/ml) of controls. Serum vitamin B12 level (190.20 ± 19.44 pg/ml) is significantly lower in diabetes mellitus patients who were suffering from the disease for more than 3.5 years as compared to serum vitamin B12 level (257.18 ± 88.74 pg/ml) of diabetes mellitus patients who were suffering from the disease for less than 3.5 years.
Conclusion: Thus, it can be concluded that there is significant vitamin B12 deficiency in type 2 diabetes mellitus patients.

THE EFFECT OF ANTI-DIABETIC DRUGS REGIMEN COMBINATION WITH METFORMIN COMPARED WITHOUT METFORMIN TO CONVERSION OF ACID-FAST BACILLUS SPUTUM SMEAR IN NEW CASE OF PULMONARYTUBERCULOSIS PATIENTS AND TYPE 2 DIABETES MELLITUS

Fransiscus A Wabia, Harun Iskandar, Husaini Umar, Syakib Bakri, Andi Makbul Aman, Hasyim Kasim, Haerani RasyidmErwin Arif, Agus Sudarso, dan Arifin Seweng

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 3843-3851

Background : This study aims to determine the effect of a combination regimen of
metformin and without metforminon the conversion of sputum smear in new cases
of pulmonary TB patients with type 2 DM.
Materials andMethods: This cross-sectional study was conducted at Wahidin Sudirohusodo
Hospital, Makassar Center for Lung Health, Kasi-Kasi, and Sudiang Community
Health Center from August 2019. This study involved 83 new cases of pulmonary
TB subjects with T2DM. New cases of pulmonary TB patients were obtained by examining AFB sputum in DM patients who had symptoms of pulmonary TB and had no history of suffering or receiving previous anti-TB drug therapy.Pulmonary TB patients receive category 1 anti-TB drugs andDM subjects were divided into 2 groups is metformin and non-metformin. Then, smear sputum is examined in the 2-month intensive phase of anti-TB drug therapy to assess the conversion of AFB sputum.
Results: From a total of 83 new cases of pulmonary TB and T2DM, 44 subjects received a combination regimen of metformin and 39 subjects non-metformin. In this study, there were 42 (95.5%) subjects who conversion sputum smear in the metformin group more higher than in the  non-metformin group but statistically it was not significant (p = 0.282).
Conclusion: There was no significant relationship between the metformin and non-metformin groups on the conversion of AFB sputum smear in new cases of pulmonary TB patients and T2DM.